Author(s): Laurie H. Sehn, Manali Kamdar, Alex F. Herrera, et al. Abstract: S802 Session topic: 21. Aggressive Non-Hodgkin lymphoma – Clinical Background Pola is an antibody-drug conjugate targeting CD79b+ cells in B-NHL. Early results led to FDA breakthrough therapy status and EMA PRIME designation. We now report combined results for safety and...
Pro zobrazení tohoto obsahu je třeba být přihlášen.